Biogen to Evaluate GlycoFi's Protein Production Platform
Monday November 10, 4:30 pm ET
LEBANON, N.H. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 10, 2003--GlycoFi, Inc. and Biogen, Inc. (NASDAQ: BGEN - News) announce the initiation of a joint research study to evaluate GlycoFi's Humanized yeast(TM) platform for the production of an undisclosed Biogen protein. The study, supported by Biogen, will combine GlycoFi's unique expression technology to produce human glycoproteins of unprecedented uniformity with Biogen's expertise in the area of therapeutic protein discovery and manufacturing.
About GlycoFi
GlycoFi, Inc. is the industry leader for the engineering and production of therapeutic glycoproteins in yeast systems. The company was founded in 2000 with the mission to be a leading biotechnology company in the development, manufacturing, and commercialization of biotherapeutics. The company has engineered yeast and other fungal protein expression systems to produce fully humanized glycoproteins, thus greatly increasing the efficiency, fidelity and scalability at which those proteins can be made. For more information, please visit www.glycofi.com. ... |
